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Edited by Francesc PosasAbstract Receptor-type protein tyrosine phosphatases (RPTPs)
are considered to transduce extracellular signals across the mem-
brane through changes in their PTP activity, however, our under-
standing of the regulatory mechanism is still limited. Here, we
show that pleiotrophin (PTN), a natural ligand for protein tyro-
sine phosphatase receptor type Z (Ptprz) (also called PTPf/
RPTPb), inactivates Ptprz through oligomerization and increases
the tyrosine phosphorylation of substrates for Ptprz, G protein-
coupled receptor kinase-interactor 1 (Git1) and membrane asso-
ciated guanylate kinase, WW and PDZ domain containing 1
(Magi1). Oligomerization of Ptprz by an artiﬁcial dimerizer or
polyclonal antibodies against its extracellular region also leads
to inactivation, indicating that Ptprz is active in the monomeric
form and inactivated by ligand-induced oligomerization.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The tyrosine phosphorylation of proteins in higher eukary-
otes serves as an important signal transduction system in a
wide variety of cellular events including cell proliferation, dif-
ferentiation, migration, metabolism, and death [1]. The net
tyrosine phosphorylation of proteins is controlled by the bal-
ance between activities of protein tyrosine kinases (PTKs)
and protein tyrosine phosphatases (PTPs). The regulatory
mechanisms of the receptor-type PTKs (RPTKs) such as
growth factor receptors have been well studied: ligand-induced
receptor dimerization leads to the transphosphorylation of key
tyrosine residues in the activation loop of the catalytic PTKAbbreviations: PTK, protein tyrosine kinase; PTP, protein tyrosine
phosphatase; Ptprz, protein tyrosine phosphatase receptor type Z;
PTN, pleiotrophin; Git1, G protein-coupled receptor kinase-interactor
1; Magi1, membrane associated guanylate kinase, WW and PDZ
domain containing 1; FKBP, FK506-binding protein
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doi:10.1016/j.febslet.2006.06.041domain, which results in the activation of RPTK [2]. In con-
trast to the regulatory mechanisms of RPTKs, those of RPTPs
are poorly understood. This is mainly due to diﬃculty in iden-
tifying the intracellular substrates for RPTPs, in addition to
the functional ligands which regulate the PTP activity from
the extracellular side.
Most of the RPTPs have a similar structure comprising a un-
ique extracellular domain, a single transmembrane domain,
and either one or two intracellular catalytic PTP domains. In
the latter case, the membrane proximal PTP domain (D1)
has the PTP activity, whereas the distal PTP domain (D2)
has little or no catalytic activity. Dimerization-induced inacti-
vation of RPTP (the dimeric inhibition model or wedge
hypothesis) has been proposed based on studies of two RPTPs,
Ptprc/CD45 [3,4] and Ptpra/PTPa [5,6], as a mechanism for the
regulation of RPTP activity. However, because no known sol-
uble ligands are available for Ptprc and Ptpra, artiﬁcial dimer-
ization methods have been used on dimeric or mutant versions
of these RPTPs. In this regard, no direct evidence that inacti-
vation indeed proceeds along with the induction of RPTP
dimerization has been obtained by monitoring the time-course
of tyrosine phosphorylation of substrate molecules in a ligand-
regulated manner.
Protein tyrosine phosphatase receptor type Z (Ptprz/PTPf/
RPTPb) is a RPTP which is predominantly expressed in the
central nervous system as a chondroitin sulfate proteoglycan
[7]. Three splicing variants of Ptprz are known: Ptprz-A, a
full-length receptor form; Ptprz-B, a short receptor form with
a deletion in the extracellular region; and Ptprz-S, a secretory
variant of Ptprz-A, which is also known as 6B4 proteoglycan
(6B4PG)/phosphacan [7]: Ptprz is also expressed in a non-pro-
teoglycan form in some tissues including the stomach [8]. Ptprz-A
and -B are composed of an N-terminal carbonic anhydrase-like
domain, a ﬁbronectin type III domain, a serine, glycine-rich
domain for chondroitin-sulfate attachment, a transmembrane
segment, and two PTP domains plus C-terminal PDZ-binding
motif. Our group found that heparin-binding growth factors,
pleiotrophin (PTN)/HB-GAM and midkine (MK), bind to
the extracellular region of Ptprz [9,10], in addition to ﬁbroblast
growth factor-2, the extracellular matrix proteins (tenascin-C,
-R), and cell adhesion molecules (Nr-CAM, L1/Ng-CAM,
F3/contactin, NCAM, and TAG1/axonin-1) by other groups
[11,12]. However, the roles of these molecules in the regulation
of Ptprz activity are largely unknown. We recently developed a
yeast substrate-trapping system for (R)PTPs, and identiﬁed
several substrates for Ptprz, including G protein-coupledblished by Elsevier B.V. All rights reserved.
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brane-associated guanylate kinase, WW, and PDZ domain-
containing 1 (Magi1) [13,14]. Thus, Ptprz is an exceptional case
among RPTPs in that candidates for its soluble ligands and
intracellular substrates are known as a set.
In the present study, we investigated the mechanism by
which ligands regulate the activity of Ptprz by monitoring
changes in the tyrosine phosphorylation of the natural sub-
strates for Ptprz. Our ﬁndings clearly indicate that oligomeri-
zation of Ptprz leads to inactivation of the PTP activity in
the living cell, and that ligand-induced oligomerization of
Ptprz transduces the extracellular signal by increasing the tyro-
sine phosphorylation of substrate molecules.2. Materials and methods
2.1. Materials
Rabbit polyclonal antibodies against Git1 and Ptprz-S (also called
6B4PG) were described previously [7,13]. Recombinant human PTN
was produced in yeast and puriﬁed as reported [15]. Expression
constructs encoding the full-length rat Ptprz-B (pZeo-PTPf), its PTP-
inactive DA mutant (pZeo-PTPfD1902A), FLAG-Git1 (pFLAG-Git1),
and FLAG-Magi1 (pFLAG-Magi1) were described previously [13,14].
The ARGENT Regulated Homodimerization Kit including AP20187
and pC4M-Fv2E was provided by ARIAD Pharmaceutical, Inc (Cam-
bridge, MA). The expression construct encoding the 2xFK506-binding
protein (FKBP)-Ptprz fusion protein (pZeo-2xFKBP-Ptprz) was gener-
ated by ligating the fragment which contains the myristoylation signal
and 2xFKBP36v domain of pC4M-Fv2E with the intracellular region of
rat Ptprz-A (amino acid residues 1668–2316; GenBank Accession No.
U09357) in the vector pZeoSV2.
2.2. Cell culture and DNA transfection
BHK-21 cells, a hamster kidney cell line, were cultured in Eagle’s
minimum essential medium with Earle’s salts supplemented with
10% fetal calf serum (FCS), in a humidiﬁed 37 C, 5% CO2 incubator.
To improve the ability of BHK-21 cells to tyrosine-phosphorylate the
cellular proteins, v-src was coexpressed with pBaBePurov-src [16]:
Five-fold increase in the tyrosine phosphorylation of cellular proteins
was reproducibly observed by this method. The DNA transfection of
expression constructs was carried out using Lipofectamine plus re-
agent (Invitrogen, Carlsbad, CA) according to the manufacturer’s
directions.
2.3. Immunoprecipitation and immunoﬂuorescence assays
Tyrosine phosphorylation of the endogenous Git1 and the FLAG-
Magi1 was analyzed by immunoprecipitation followed by Western
blotting as described previously [13,14]. Signal intensity of the bands
was quantiﬁed by densitometry, and analyzed by ANOVA.When a sig-
niﬁcant interaction was found (P < 0.05), a post hoc comparison (Sche-
ﬀe’s test) was performed with Stat View software (version 5.0J; SAS
Institute, Cary, NC). An immunocytochemical study of Ptprz-B was
performed as follows. Cells were washed three times with phosphate-
buﬀered saline (PBS), ﬁxed with 4% paraformaldehyde/PBS for
15 min, and then blocked with 3% skimmed milk/PBS for 30 min.
The cells were incubated with anti-Ptprz-S antibody (1 lg/ml) for 3 h.
Bound antibodies were visualized with Alexa488-conjugated anti-
rabbit antibody (Molecular Probes, Eugene, OR) and observed using
a Zeiss LSM510 confocal microscope (Carl Zeiss, Jena, German). All
results are representative of three independent experiments.3. Results
3.1. PTN stimulates tyrosine phosphorylation of substrates for
Ptprz
First of all, we veriﬁed that exogenously expressed wild-type
Ptprz-B (Ptprz-B-WT) dephosphorylates substrate molecules,Git1 and Magi1, in vivo by using BHK-21 cells, which do
not express any isoform of Ptprz endogenously. Tyrosine
phosphorylation of the substrates was estimated by immuno-
precipitation followed by Western blotting with anti-phospho-
tyrosine antibody. As shown in Fig. 1A, the level of tyrosine
phosphorylation of Git1 in cells expressing Ptprz-B-WT was
signiﬁcantly lower than that in mock-transfected cells in the
absence of ligand, PTN (pY; lanes 1 and 3), suggesting that
Ptprz-B-WT is constitutively active and dephosphorylates
Git1 in vivo. Of note is that Ptprz-B is expressed in a non-pro-
teoglycan form in BHK-21 cells (Fig. 1A, bottom).
Upon the application of PTN, the tyrosine phosphorylation
of Git1 was markedly upregulated, suggesting that ligand-
binding to Ptprz-B-WT inactivates the PTP activity (Fig. 1A,
lanes 3 and 4). Such an eﬀect was observed in cells expressing
Ptprz-B-WT, but not in mock-transfected (lanes 1 and 2) or
PTP-inactive DA mutant of Ptprz-B (Ptprz-B-DA)-transfected
(lanes 5 and 6) cells, indicating that this is attributable to an
inhibition of Ptprz activity: Because BHK-21 cells are devoid
of endogenous Ptprz expression, Ptprz-B-DA does not show
a dominant-negative eﬀect. When the total cell lysate was ana-
lyzed with anti-phosphotyrosine antibody, overall tyrosine-
phosphorylation patterns appeared identical among samples
(Fig. 1B). This indicates that the expression of Ptprz-B-WT
or Ptprz-B-DA had no non-speciﬁc eﬀects on the tyrosine
phosphorylation of cellular proteins. When BHK-21 cells
expressing Ptprz-B-WT were treated with PTN, Git1 exhibited
a signiﬁcant increase in tyrosine phosphorylation in a dose-
and time-dependent manner (Fig. 1C and D). The same eﬀects
of PTN were observed on another substrate, Magi1 [14]
(Fig. 1E and F). Thus, PTN is similarly but speciﬁcally eﬀec-
tive in the tyrosine phosphorylation of substrate molecules
for Ptprz.
To know the distribution of Ptprz on the cell surface upon
PTN treatment, we visualized Ptprz-B-WT with immunoﬂuo-
rescence using speciﬁc antibodies against the extracellular re-
gion without permeabilization. Ptprz-B was distributed
diﬀusely in the cell membrane without PTN treatment,
whereas large clusters of Ptprz-B were observed in patches
1 h after the treatment (Fig. 1G). These results suggest that
PTN induces the clustering of Ptprz on the cell surface, which
consequently leads to the inactivation of Ptprz.
3.2. Oligomerization of the intracellular region of Ptprz leads to
inhibition of its PTP activity
To verify this view that the dimerization (or oligomerization)
of Ptprz leads to the inactivation, we ﬁrst adopted an artiﬁcial
dimerizer system which induces the dimerization of target mol-
ecules in vivo [17]. In this system, the target protein is fused
with a FKBP, which binds to a chemical inducer of dimeriza-
tion, AP20187 (Fig. 2A). AP20187 is a cell-permeant small or-
ganic molecule with two identical motifs, each of which binds
with FKBP resulting in a homodimerization of target proteins
containing FKBP. As shown in Fig. 2A, the entire intracellular
domain of the receptor form of Ptprz was fused at its N-termi-
nus with the myristoylation signal for recruitment to the plas-
ma membrane and then with two FKBPs in tandem. The
fusion protein, 2xFKBP-Ptprz, is oligomerized in the presence
of AP20187 (Fig. 2A).
In the absence of AP20187, the level of tyrosine phosphory-
lation of Git1 in cells expressing 2xFKBP-Ptprz-WT was sig-
niﬁcantly lower than that of mock-transfected cells (Fig. 2B,
Fig. 1. PTN inactivates Ptprz and induces clustering of Ptprz. (A) PTN treatment (100 ng/ml, 1 h) increased the tyrosine phosphorylation of Git1 in
cells expressing the wild-type Ptprz-B (WT), but not in mock-transfected (Mock) or PTP-inactive DA mutant of Ptprz-B (DA)-transfected cells
(upper). Signal intensities were quantiﬁed and expressed below as the percentage compared with the vehicle-treated control of mock-transfected cells
(control cells, lane 1). Data are presented as the means ± S.E. (n = 3). **P < 0.01, as compared with control cells. ##P < 0.01, as compared between
vehicle and PTN treatments. Ptprz-B expression was conﬁrmed equal using cell lysates without chondroitinase ABC treatment by Western blotting
with anti-Ptprz-S antibody (lower). (B) The cell lysates in (A) were analyzed by Western blotting with anti-phosphotyrosine antibody. Overall
tyrosine-phosphorylation patterns were identical among the three groups irrespective of PTN treatment. (C–F) PTN increased the tyrosine
phosphorylation of Git1 (C,D) and Magi1 (E,F) in a dose- (1 h) and time- (100 ng/ml) dependent manner. Signal intensities were quantiﬁed and
expressed below as the percentage compared with control cells (lane 1). Data are the means ± S.E. (n = 3). *P < 0.05 and **P < 0.01, with control
cells. (G) Localization of Ptprz-B after treatment with PTN. A patchy distribution of Ptprz-B on the surface was found in PTN-treated (100 ng/ml,
1 h) cells (right; arrowheads), whereas a diﬀuse distribution was observed in control cells (left). Top, ﬂuorescent images (inverted grayscale); middle,
enlargements of the area enclosed by a square in the top panels; bottom, diﬀerential interference contrast (DIC) images. Scale bars, 20 lm.
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mer is constitutively active and dephosphorylates substrates as
in the case of Ptprz-B-WT. Upon AP20187 treatment of the
cells expressing 2xFKBP-Ptprz-WT, tyrosine phosphorylation
of Git1 (Fig. 2B and C) and Magi1 (Fig. 2D) was signiﬁcantly
increased. This occurred in a dose-dependent manner (Fig. 2B,
lanes 3–6), and in a time-dependent manner (Fig. 2C, lanes 6–
10). On the other hand, no signiﬁcant increase in the tyrosine
phosphorylation of Git1 (Fig. 2B and C) or Magi1 (Fig. 2D)
was detected when mock-transfected or 2xFKBP-Ptprz-DA-
transfected cells were treated with AP20187. These results indi-
cate that oligomerization of the intracellular region of Ptprz
leads to an inactivation of its PTP activity, and consequently
an increase in the tyrosine phosphorylation of substrate mole-cules. It should be noted that the tyrosine phosphorylation of
both substrates in the cells expressing 2xFKBP-Ptprz-WT after
the treatment with AP20187 at 100 nM was nearly equal to
that in the mock-transfected cells (Fig. 2B, lanes 1 and 5;
and D, lanes 1 and 4). The amount of proteins for 2xFKBP-
Ptprz, Git1, and Magi1 did not change during the period of
monitoring (data not shown).
3.3. Anti-Ptprz-S antibodies induce inhibition of Ptprz activity
Moreover, we examined the eﬀects of oligomerization of the
native form of Ptprz-B on its PTP activity, by using anti-Ptprz-
S antibodies, rabbit polyclonal antibodies against the extracel-
lular region of Ptprz [7]. The anti-Ptprz-S antibodies dose- and
time-dependently enhanced the tyrosine phosphorylation of
Fig. 2. Oligomerization of Ptprz by the dimerizer inactivates the PTP activity. (A) Structure of Ptprz-A/B (left) and 2xFKBP-Ptprz (right) and a
schematic representation of the clustering of 2xFKBP-Ptprz caused by AP20187 (right). (B,C) AP20187-indcued oligomerization of 2xFKBP-Ptprz-
WT enhanced the tyrosine phosphorylation of Git1 in a dose- (1 h) and time- (100 nM) dependent manner. (D) AP20187-induced oligomerization of
2xFKBP-Ptprz-WT increased the tyrosine phosphorylation of Magi1. Signal intensities were quantiﬁed and expressed below as the percentage
compared with control cells (lane 1). Data are the means ± S.E. (n = 3). **P < 0.01, as compared with control cells. ##P < 0.01, as compared in the
same group.
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(Fig. 3A and B). On the other hand, mock-transfected or
Ptprz-B-DA-transfected cells showed no signiﬁcant change in
the tyrosine phosphorylation of Git1 (Fig. 3C) and Magi1
(Fig. 3D) upon the antibody treatment. We conﬁrmed that
control antibodies have no eﬀect on the phosphorylation of
substrates (Fig. 3C and D). As expected, Ptprz-B on the cell
surface showed a clustered localization after the treatment with
anti-Ptprz-S antibodies, but not with control antibodies
(Fig. 3E). Of note is that the time-course of Ptprz-B clustering
after the antibody treatment (Fig. 3F) correlated well with that
of an increase in the tyrosine phosphorylation of Git1
(Fig. 3B). In these experiments, the amount of Git1 and Magi1
expressed in the cells was not altered by the antibody treat-
ment, and no substantial internalization of Ptprz-B was ob-
served at 60 min after treatment (data not shown). These
results indicate that anti-Ptprz-S antibodies induce clustering
of Ptprz on the cell surface, which consequently leads to an
inactivation of Ptprz.4. Discussion
In the present study, we showed that the tyrosine phos-
phorylation of substrates for Ptprz is enhanced by the oligo-
merization of Ptprz induced on the cell surface. As the
tyrosine phosphorylation of cellular proteins is thought to
be balanced by the activity of both PTKs and PTPs, we rea-
soned that the increase in tyrosine phosphorylation of sub-
strates is a result of an inactivation of Ptprz. We also
demonstrated that ligand-binding leads to inactivation of
Ptprz. Our results suggest that PTN downregulates the Ptprzactivity through oligomerization in vivo. It is noteworthy that
the time-course of Ptprz inactivation is rather slow, taking
60–120 min for the full inactivation. Importantly, the time-
courses were similar among the three diﬀerent clustering
methods for Ptprz. Therefore, such a slow kinetics might be
a speciﬁc character of Ptprz.
As for the dimeric inhibition model, the juxtamembrane
wedge region has been reported to play a pivotal role in di-
meric inhibition for Ptpra and Ptprc [4–6]. The wedge is a con-
served motif present in the large family of RPTPs [5], in that
two acidic residues (D227/D228 in the human Ptpra and
D623/E624 in the human Ptprc) in the wedge are reportedly
important for inhibiting PTP [4]. However, these acidic resi-
dues are not conserved in Ptprz (S1715/N1716 in rat and
S1713/S1714 in human). Therefore, it is not clear whether
the wedge hypothesis is directly applicable to the dimeric inhi-
bition of Ptprz. Furthermore, intermolecular interactions
among diﬀerent RPTPs were also reported [18]. Ptprz has
another subfamily member, Ptprg/PTPc. Ptprz may have inter-
actions with Ptpra and Ptprm/PTPl [19]. We should not rule
out the possibility of hetero-oligomerization as a regulatory
mechanism in vivo. Besides the dimeric inhibition model,
redox-dependent regulation of PTP activity, which is reversibly
inhibited by oxidation of the catalytic cystein by cellular
oxidants such as hydrogen peroxide (H2O2), has been reported
(reviewed in [20]). Dimerization and oxidation have been
thought to be independent mechanisms for the regulation of
RPTP activity, but H2O2 was recently revealed to stabilize
the Ptpra dimers [21].
We previously reported that the application of PTN-coated
latex beads to neuroblastoma B103 cells increased the tyro-
sine phosphorylation of Git1, along with the accumulation
Fig. 3. Polyclonal antibodies against the extracellular region of Ptprz induce clustering of Ptprz and inhibition of Ptprz activity. (A) Treatment with
anti-Ptprz-S antibodies (1 h) dose-dependently enhanced the tyrosine phosphorylation of Git1. (B) Time-course of tyrosine phosphorylation of Git1
after treatment with anti-Ptprz-S antibodies at 10 lg/ml. (C,D) Treatment with 10 lg/ml of speciﬁc anti-Ptprz-S antibodies (s), but not control Igs (c)
increased the tyrosine phosphorylation of Git1 and Magi1 in cells expressing Ptprz-B-WT (WT), but not in the mock-transfected (Mock) or Ptprz-B-
DA-transfected (DA) cells. Signal intensities were quantiﬁed and expressed below as the percentage compared with control cells (lane 1). Data are the
means ± S.E. (n = 3). *P < 0.05 and **P < 0.01, as compared with control cells. #P < 0.05 and ##P < 0.01, as compared in the same group. (E)
Immunocytochemical localization of Ptprz-B after treatment with anti-Ptprz-S antibodies or control Igs (10 lg/ml, 1 h). Clustering of Ptprz-B on the
cell surface was speciﬁcally induced by anti-Ptprz antibodies (arrowheads), but not by control Igs. Left, ﬂuorescent images (inverted grayscale);
middle, enlargements of the area enclosed by a square in the left panels; right, DIC images. Scale bars, 20 lm. (F) Time-course of the clustering of
Ptprz-B induced by anti-Ptprz-S antibodies (10 lg/ml). Top, ﬂuorescent images (inverted grayscale); bottom, DIC images. Scale bars, 20 lm.
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showed that VacA, a cytotoxin secreted by Helicobacter py-
lori, behaves as a ligand for Ptprz and the erroneous Ptprz
signaling by VacA causes gastric tissue damage leading to
gastric ulcer [8]. Of note is that the majority of the isoform
expressed in the stomach is the non-proteoglycan form of
Ptprz-B [8]. VacA, as well as PTN, stimulates tyrosine phos-
phorylation of Git1 in BHK-21 cells expressing Ptprz-B in a
non-proteoglycan form [8]. Because VacA has a tendency to
assemble and form a hexamer [22], it is possible that VacA
also induces the inactivation of Ptprz through oligomeriza-
tion. However, most of the Ptprz isoforms expressed in the
brain are predominantly synthesized as proteoglycans [7]. Be-
cause of the highly sulfated sugar moieties in the extracellular
region, formation of the Ptprz dimer (oligomer) in brain tis-
sue seems to be diﬃcult. For this reason, we do not rule out
the possibility that regulatory mechanisms for Ptprz other
than oligomerization may exist, especially for Ptprz in the
proteoglycan form.Although various biological activities of PTN have been
reported [23], the signaling mechanisms through Ptprz largely
remain to be elucidated. So far, Git1 [13,14], b-catenin [24],
p190 RhoGAP [14,25], and also Magi1 (Fig. 1E and F), have
been identiﬁed as substrates for Ptprz in response to ligand-
binding. We previously demonstrated that the migration of
cortical neurons on glass ﬁbers was stimulated by PTN coating
[26]. Because over-expression of Git1 in ﬁbroblasts enhances
cell motility [27], it is plausible that Ptprz signal is involved
in neural migration by modulating the function of Git1. We
also demonstrated that Ptprz-deﬁcient mice exhibit abnormal-
ities in hippocampus-dependent memory formation [25,28],
probably due to the aberrant regulation of p190 RhoGAP
activity [25]. Membrane-associated guanylate kinase (MA-
GUK) family proteins including Magi1 are known to function
as a molecular scaﬀold for the assembly of proteins into mul-
tiprotein complexes [29]. The interaction between Ptprz and
Magi1 was thought to be mediated primarily via the PDZ do-
main in vivo from the results of substrate-trapping experiments
4056 M. Fukada et al. / FEBS Letters 580 (2006) 4051–4056[14]: The third PDZ domain of Magi1 is responsible for inter-
action with the carboxyl terminal PDZ-binding motif of Ptprz
(M. Fukada and M. Noda, unpublished observations). On the
other hand, b-catenin, another substrate for Ptprz [24], has
been reported to bind to the ﬁfth PDZ domain of Magi1
[30]. The tyrosine phosphorylation of b-catenin in U373-MG
glioblastoma cells, which endogenously express Ptprz, is
upregulated upon treatment with the PTN-Fc fusion protein
[24]. Thus, it is likely that Magi1 functions not only as a signal
mediator but also as a molecular scaﬀold to assemble the sig-
naling complexes of Ptprz and its substrates. Noteworthily, the
time-course of molecular clustering by anti-Ptprz-S antibody
was almost similar between the wild-type and a mutant Ptprz
deﬁcient in the PDZ-binding ability in BHK-21 cells (data
not shown). An understanding of the functional relevance of
the change in tyrosine phosphorylation of the respective sub-
strates to speciﬁc cellular events will be required in order to
dissect Ptprz signaling.
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